Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible?

Michele Emdin, Cinzia Fatini, Gianluca Mirizzi, Roberta Poletti, Chiara Borrelli, Concetta Prontera, Roberto Latini, Claudio Passino, Aldo Clerico, Giuseppe Vergaro

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Renin-angiotensin-aldosterone system (RAAS), participated by kidney, liver, vascular endothelium, and adrenal cortex, and counter-regulated by cardiac endocrine function, is a complex endocrine system regulating systemic functions, such as body salt and water homeostasis and vasomotion, in order to allow the accomplishment of physiological tasks, such as orthostasis, physical and emotional stimuli, and to react towards the hemorrhagic insult, in tight conjunction with other neurohormonal axes, namely the sympathetic nervous system, the endothelin and vasopressin systems. The systemic as well as the tissue RAAS are also dedicated to promote tissue remodeling, particularly relevant after damage, when chronic activation may configure as a maladaptive response, leading to fibrosis, hypertrophy and apoptosis, and organ dysfunction. RAAS activation is a fingerprint of systemic arterial hypertension, kidney dysfunction, vascular atherosclerotic disease, and is definitely an hallmark of heart failure, which rapidly shifts from organ disease to a disorder of neurohormonal regulatory systems. Chronic RAAS activation is an indirect or direct target of most effective pharmacological treatments in heart failure, such as beta-blockers, inhibitors of angiotensin converting enzyme, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor blockers. Biomarkers of RAAS activation are available, with different feasibility and accuracy, such as plasma renin activity, renin, angiotensin II, and aldosterone, which all accompany the increasing clinical severity of heart failure disease, and are well recognized prognostic factors, even in patients with optimal therapy. Polymorphisms influencing the expression and activity of RAAS pathways have been recognized as clinically relevant biomarkers, likely influencing either the individual clinical phenotype, or the response to drugs. This solid, growing evidence strongly suggests the rationale for the use of biomarkers of the RAAS activation, as a guide to tailor individual therapy in the current practice, and their implementation as a rule-in marker for future trials on novel drugs in the heart failure setting.

Original languageEnglish
Pages (from-to)85-93
Number of pages9
JournalClinica Chimica Acta
Volume443
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Angiotensins
Biomarkers
Renin-Angiotensin System
Aldosterone
Renin
Heart Failure
Chemical activation
Kidney
Mineralocorticoid Receptors
Endocrine System
Body Water
Angiotensin Receptor Antagonists
Adrenal Cortex
Endothelins
Sympathetic Nervous System
Vascular Endothelium
Dermatoglyphics
Dizziness
Vasopressins
Vascular Diseases

Keywords

  • Aldosterone
  • Angiotensin
  • Biomarkers
  • Heart failure
  • Renin

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

Emdin, M., Fatini, C., Mirizzi, G., Poletti, R., Borrelli, C., Prontera, C., ... Vergaro, G. (2015). Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible? Clinica Chimica Acta, 443, 85-93. https://doi.org/10.1016/j.cca.2014.10.031

Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure : How useful, how feasible? / Emdin, Michele; Fatini, Cinzia; Mirizzi, Gianluca; Poletti, Roberta; Borrelli, Chiara; Prontera, Concetta; Latini, Roberto; Passino, Claudio; Clerico, Aldo; Vergaro, Giuseppe.

In: Clinica Chimica Acta, Vol. 443, 01.03.2015, p. 85-93.

Research output: Contribution to journalArticle

Emdin, M, Fatini, C, Mirizzi, G, Poletti, R, Borrelli, C, Prontera, C, Latini, R, Passino, C, Clerico, A & Vergaro, G 2015, 'Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible?', Clinica Chimica Acta, vol. 443, pp. 85-93. https://doi.org/10.1016/j.cca.2014.10.031
Emdin, Michele ; Fatini, Cinzia ; Mirizzi, Gianluca ; Poletti, Roberta ; Borrelli, Chiara ; Prontera, Concetta ; Latini, Roberto ; Passino, Claudio ; Clerico, Aldo ; Vergaro, Giuseppe. / Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure : How useful, how feasible?. In: Clinica Chimica Acta. 2015 ; Vol. 443. pp. 85-93.
@article{a8def75cb2f04e3a8bd52df0ceb267ca,
title = "Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: How useful, how feasible?",
abstract = "Renin-angiotensin-aldosterone system (RAAS), participated by kidney, liver, vascular endothelium, and adrenal cortex, and counter-regulated by cardiac endocrine function, is a complex endocrine system regulating systemic functions, such as body salt and water homeostasis and vasomotion, in order to allow the accomplishment of physiological tasks, such as orthostasis, physical and emotional stimuli, and to react towards the hemorrhagic insult, in tight conjunction with other neurohormonal axes, namely the sympathetic nervous system, the endothelin and vasopressin systems. The systemic as well as the tissue RAAS are also dedicated to promote tissue remodeling, particularly relevant after damage, when chronic activation may configure as a maladaptive response, leading to fibrosis, hypertrophy and apoptosis, and organ dysfunction. RAAS activation is a fingerprint of systemic arterial hypertension, kidney dysfunction, vascular atherosclerotic disease, and is definitely an hallmark of heart failure, which rapidly shifts from organ disease to a disorder of neurohormonal regulatory systems. Chronic RAAS activation is an indirect or direct target of most effective pharmacological treatments in heart failure, such as beta-blockers, inhibitors of angiotensin converting enzyme, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor blockers. Biomarkers of RAAS activation are available, with different feasibility and accuracy, such as plasma renin activity, renin, angiotensin II, and aldosterone, which all accompany the increasing clinical severity of heart failure disease, and are well recognized prognostic factors, even in patients with optimal therapy. Polymorphisms influencing the expression and activity of RAAS pathways have been recognized as clinically relevant biomarkers, likely influencing either the individual clinical phenotype, or the response to drugs. This solid, growing evidence strongly suggests the rationale for the use of biomarkers of the RAAS activation, as a guide to tailor individual therapy in the current practice, and their implementation as a rule-in marker for future trials on novel drugs in the heart failure setting.",
keywords = "Aldosterone, Angiotensin, Biomarkers, Heart failure, Renin",
author = "Michele Emdin and Cinzia Fatini and Gianluca Mirizzi and Roberta Poletti and Chiara Borrelli and Concetta Prontera and Roberto Latini and Claudio Passino and Aldo Clerico and Giuseppe Vergaro",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.cca.2014.10.031",
language = "English",
volume = "443",
pages = "85--93",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure

T2 - How useful, how feasible?

AU - Emdin, Michele

AU - Fatini, Cinzia

AU - Mirizzi, Gianluca

AU - Poletti, Roberta

AU - Borrelli, Chiara

AU - Prontera, Concetta

AU - Latini, Roberto

AU - Passino, Claudio

AU - Clerico, Aldo

AU - Vergaro, Giuseppe

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Renin-angiotensin-aldosterone system (RAAS), participated by kidney, liver, vascular endothelium, and adrenal cortex, and counter-regulated by cardiac endocrine function, is a complex endocrine system regulating systemic functions, such as body salt and water homeostasis and vasomotion, in order to allow the accomplishment of physiological tasks, such as orthostasis, physical and emotional stimuli, and to react towards the hemorrhagic insult, in tight conjunction with other neurohormonal axes, namely the sympathetic nervous system, the endothelin and vasopressin systems. The systemic as well as the tissue RAAS are also dedicated to promote tissue remodeling, particularly relevant after damage, when chronic activation may configure as a maladaptive response, leading to fibrosis, hypertrophy and apoptosis, and organ dysfunction. RAAS activation is a fingerprint of systemic arterial hypertension, kidney dysfunction, vascular atherosclerotic disease, and is definitely an hallmark of heart failure, which rapidly shifts from organ disease to a disorder of neurohormonal regulatory systems. Chronic RAAS activation is an indirect or direct target of most effective pharmacological treatments in heart failure, such as beta-blockers, inhibitors of angiotensin converting enzyme, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor blockers. Biomarkers of RAAS activation are available, with different feasibility and accuracy, such as plasma renin activity, renin, angiotensin II, and aldosterone, which all accompany the increasing clinical severity of heart failure disease, and are well recognized prognostic factors, even in patients with optimal therapy. Polymorphisms influencing the expression and activity of RAAS pathways have been recognized as clinically relevant biomarkers, likely influencing either the individual clinical phenotype, or the response to drugs. This solid, growing evidence strongly suggests the rationale for the use of biomarkers of the RAAS activation, as a guide to tailor individual therapy in the current practice, and their implementation as a rule-in marker for future trials on novel drugs in the heart failure setting.

AB - Renin-angiotensin-aldosterone system (RAAS), participated by kidney, liver, vascular endothelium, and adrenal cortex, and counter-regulated by cardiac endocrine function, is a complex endocrine system regulating systemic functions, such as body salt and water homeostasis and vasomotion, in order to allow the accomplishment of physiological tasks, such as orthostasis, physical and emotional stimuli, and to react towards the hemorrhagic insult, in tight conjunction with other neurohormonal axes, namely the sympathetic nervous system, the endothelin and vasopressin systems. The systemic as well as the tissue RAAS are also dedicated to promote tissue remodeling, particularly relevant after damage, when chronic activation may configure as a maladaptive response, leading to fibrosis, hypertrophy and apoptosis, and organ dysfunction. RAAS activation is a fingerprint of systemic arterial hypertension, kidney dysfunction, vascular atherosclerotic disease, and is definitely an hallmark of heart failure, which rapidly shifts from organ disease to a disorder of neurohormonal regulatory systems. Chronic RAAS activation is an indirect or direct target of most effective pharmacological treatments in heart failure, such as beta-blockers, inhibitors of angiotensin converting enzyme, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor blockers. Biomarkers of RAAS activation are available, with different feasibility and accuracy, such as plasma renin activity, renin, angiotensin II, and aldosterone, which all accompany the increasing clinical severity of heart failure disease, and are well recognized prognostic factors, even in patients with optimal therapy. Polymorphisms influencing the expression and activity of RAAS pathways have been recognized as clinically relevant biomarkers, likely influencing either the individual clinical phenotype, or the response to drugs. This solid, growing evidence strongly suggests the rationale for the use of biomarkers of the RAAS activation, as a guide to tailor individual therapy in the current practice, and their implementation as a rule-in marker for future trials on novel drugs in the heart failure setting.

KW - Aldosterone

KW - Angiotensin

KW - Biomarkers

KW - Heart failure

KW - Renin

UR - http://www.scopus.com/inward/record.url?scp=84924261086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924261086&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.10.031

DO - 10.1016/j.cca.2014.10.031

M3 - Article

C2 - 25445411

AN - SCOPUS:84924261086

VL - 443

SP - 85

EP - 93

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -